Gracell Biotechnologies Completes $85 Million Series B for Immune Cell Gene Therapies

Gracell addresses the issues of complex manufacture and high cost of cellular gene therapeutics SUZHOU and SHANGHAI, China, Feb. 25, 2019 -- (Healthcare Sales & Marketing Network) -- Gracell Biotechnologies, Co., Ltd. ("Gracell") announced th... Biopharmaceuticals, Venture Capital Gracell Biotechnologies
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news